Evaluation, assays and treatment of pkal-mediated disorders
AssigneeDyax Corp.
InventorsKusumam Joseph, Allen P. Kaplan
Life of this patent
Estimating the term…
Abstract
The invention provides assay methods of detecting last protease CI inhibitor (C1-INH) that binds plasma kallikreir, Factor XII, or both, and uses thereof for identifying subjects at risk for or suffering from a pKal-me-diated or bradykinin-mediated disorder. Provided methods permit analysis of patients with plasma kallikrein-mediated angioedema (KMA), or other diseases mediated by pKal useful in the evaluation and treatment.
Claims21
-39. (canceled)
A method of treating a subject having a plasma kallikrein (pKal)-mediated disorder, the method comprising:
- (i) contacting a sample obtained from the subject containing plasma protease C1 inhibitor (C1-INH) with a capture reagent;
- wherein the capture reagent comprises:
- a) an active form of Factor XII, or a C1-INH binding fragment thereof,
- b) an active form of pKal, or a C1-INH binding fragment thereof, or
- c) a combination of a) and b);
- (ii) measuring a level of the C1-INH in the sample that binds to the capture reagent,
- (iii) identifying the subject as being at risk for or having a pKal-mediated disorder, wherein the level of the C1-INH obtained in step (i) being reduced relative to the level of the C1-INH in a healthy subject is indicative of risk or occurrence of the pKal-mediated disorder;
- and
- (iv) administering to the subject identified in step (iii) an effective amount of a therapeutic agent.
A method for treating a subject having a plasma kallikrein (pKal)-mediated disorder, the method comprising administering to the subject an effective amount of a therapeutic agent,
- wherein the subject has a reduced level of plasma protease C1 inhibitor (C1-INH) that is capable of binding to a capture reagent as compared to a reference value, and
- wherein the capture reagent comprises:
- i) an active form of Factor XII, or a C1-INH-binding fragment thereof;
- ii) an active form of pKal, or a C1-INH-binding fragment thereof, or
- iii) a combination of i) and ii).
Dependencies are inferred from the claim text.